Companies/AnaptysBio, Inc.

Company profile

AnaptysBio, Inc.

NASDAQ: ANAB · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001370053Reports USD

#280 of 1,422 Healthcare companies by revenuetop-quartile growth

EA Score

75B+

FH 81DQ 72GM 69SS 65

v0.1 · 65/100 weight · provisional

↑ 3-yr revenue growth, operating margin · ↓ growth stability, listing tenure

Methodology →

Revenue TTM

$232.4M

Rev growth YoY (TTM)

+107.7%

Net income (FY)

-$13.2M

Employees

104

as of 2026-08-08

Market cap

$1.7B

as of 2026-08-08

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$234.6M$234.6M2025

Net income-$13.2M-$13.2M2025

Operating income$47.9M$47.9M2025

Total assets$364.4M$364.4M2025

Equity$37.2M$37.2M2025

Revenue trend

FY2019 – FY2025 · USD

$5.0M

FY19

$8.0M

FY19

$75.0M

FY20

$63.2M

FY21

$10.3M

FY22

$17.2M

FY23

$91.3M

FY24

$234.6M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is AnaptysBio, Inc.’s revenue?

AnaptysBio, Inc. booked $234.6M in FY2025 revenue, growing 157% year over year — faster than most Healthcare companies we track, at a -5.6% net margin.

Peers · Healthcare

Vaxart, Inc.72B OrthoPediatrics Corp.69B Akebia Therapeutics, Inc.66B Cerus Corporation74B Talkspace, Inc.71B Puma Biotechnology, Inc.72B

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B60C Sempra$12.4B64C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+

Key facts

CEODaniel Faga

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: ANAB

Employees104

IPO date2017-01-26

Latest filings

8-K2026-08-11 8-K2026-07-30 DEF 14A2026-06-29 8-K2026-06-22 8-K2026-05-29 8-K2026-05-21 8-K2026-05-12 10-Q2026-05-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.